CANF — Can Fite Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $14.60m
- $9.77m
- $0.67m
Annual cashflow statement for Can Fite Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.4 | -12.6 | -10.2 | -7.63 | -7.88 |
| Depreciation | |||||
| Non-Cash Items | 1.93 | 0.313 | 0.659 | 0.122 | 0.503 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.443 | 2.43 | -1.3 | -0.943 | -0.267 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.1 | -9.86 | -10.8 | -8.44 | -7.64 |
| Capital Expenditures | -0.026 | -0.011 | -0.009 | -0.002 | -0.005 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -14.5 | 9.51 | 0.5 | 1.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.026 | -14.5 | 9.5 | 0.498 | 1.5 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 17.7 | 20.5 | 0 | 9.14 | 6.71 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.57 | -3.88 | -1.41 | 1.3 | 0.547 |